As shown in Fig. 4, combined treatment with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12 showed marked inhibitory effect on the intrahepatic implanted tumors; and after 14 days, this combination therapy had resulted in 6.5-fold greater reduction in the tumor bioluminescence imaging (P <0.001) compared to a therapy with Ad-ΔB (Fig. 4). This evidence concerns the gene TNFSF10 and neoplasm.